Form 4 for COCH Envoy Medical, Inc.
Accepted 2026-02-17 00:00:00 ET · period of report 2026-02-12 · accession 0001104659-26-016182 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-17 | 2026-02-12 | COCH | TAYLOR GLEN A | 10% | P - Purchase | $0.4 | +18.75M | 21.70M | +635% | +$7.50M |
| DM | 2026-02-17 | 2026-02-12 | COCH | TAYLOR GLEN A | 10% | P - Purchase | $0.00 | +30.00M | 11.25M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-02-12 | P | A | 18,750,000 | $0.4 | 21,703,607 | D | — | — | |
| 2 | Derivative | Warrant Shares (Series A-2) | 2026-02-12 | P | A | 18,750,000 | $0.00 | 18,750,000 | D | $0.4 · — to — | 18,750,000 Class A Common Stock | (F3) The Series A-1 Warrants and Series A-2 Warrants (the "Common Warrants") will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants (the "Stockholder Approval Date"). (F5) The Series A-2 Warrants expire on the earlier of (i) the sixty-month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has received U.S. Food and Drug Administration approval for its Acclaim cochlear implant (the "Series A-2 Milestone Event"). |
| 3 | Derivative | Warrant Shares (Series A-1) | 2026-02-12 | P | A | 11,250,000 | $0.00 | 11,250,000 | D | $0.4 · — to — | 11,250,000 Class A Common Stock | (F3) The Series A-1 Warrants and Series A-2 Warrants (the "Common Warrants") will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants (the "Stockholder Approval Date"). (F4) The Series A-1 Warrants expire on the earlier of (i) the twenty-four month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration for its Acclaim cochlear implant (the "Series A-1 Milestone Event"). |